EbleA.S., ThorpeS.R., BaynesJ.W.Nonenzymatic glycosylation and glucose-dependent cross-linking of protein.J Biol Chem1983; 258: 9406–12.
4.
VlassaraH., BucalaR., StrikerL.Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.Lab Invest1991; 70: 138–51.
5.
VlassaraH.Recent progress on the biologic and clinical significance of advanced glycosylation end products.J Lab Clin Med1994; 124: 19–30.
6.
MakitaZ., RadoffS., RayfieldE.J.Advanced glycosylation endproducts in patients with diabetic nephropathy.N Engl J Med1991; 325: 836–42.
7.
MakitaZ., BucalaR., RayfieldE.J.Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.Lancet1994; 343: 1519–22.
8.
PapanastasiouP., GrassL., RodelaH., PatrikareaA., OreopoulosD., DiamandisE.P.Immunological quantification of advanced glycosylation endproducts in the serum of patients on haemo dialysis or CAPD.Kidney Int1994; 46: 216–22.
9.
Dolhofer-BliesenerR., LechnerB., DeppischR., RitzE., GerbitzK.D.Immunological determination of advanced glycosylation endproducts in human blood and urine.Nephrol Dial Transplant1995; 10: 657–64.
10.
VlassaraH.Serum advanced glycosylation endproducts: a new class of uraemic toxins?Blood Purif1994; 12: 54–9.
11.
DobbieJ.W.New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis.Am J Kidney Dis1990; 15: 97–109.
12.
WilliamsonJ.R., KiloC.Basement membrane thickening and diabetic microangiopathy.Diabetes1976; 25(Suppl 2): 925–7.
13.
WilliamsonJ.R., KiloC.Capillary basement membrane thickening in diabetes.Diabetes1983; 32(Suppl 2): 96–100.
14.
BrownleeM., VlassaraH., CeramiA.Nonenzymatic glycosylation and the pathogenesis of diabetic complications.Ann Intern Med1984; 101: 527–37.
15.
GotloibL., Bar-SellaP., ShostakA.Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: ultrastructural changes of reduplicated peritoneal basement membrane.Perit Dial Bull1985; 5: 212–15.
16.
Di PaoloN., SacchiG.Peritoneal vascular changes in continuous ambulatory dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy.Perit Dial Int1989; 9: 41–5.
17.
DobbieJ.W.Morphology of the peritoneum in CAPD.Blood Purif1989; 7: 74–85.
18.
DobbieJ.W.Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.Perit Dial Int1992; 12: 14–27.
19.
Di PaoloN., SacchiG., De MiaM.Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis.Nephron1986; 44: 204–11.
20.
DobbieJ.W., LloydJ.K., GallC.A.Categorisation of ultrastructural changes in peritoneal mesothelium, stroma and blood vesels in uraemia and CAPD patients. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G. eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin Inc., 1990; 6: 3–12.
21.
TookeJ.E.Microcirculation and diabetes.Br Med Bull1989; 45: 206–23.
22.
LambE., Cat tellW.R., DawnayA.Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis.Clin Sci1993; 84: 619–26.
23.
LambE., Cat tellW.R., DawnayA.In vitro formation of advanced glycation endproducts in peritoneal dialysis fluid.Kidney Int1995; 47: 1768–74.
WieslanderA.P., DeppischR., SvenssonE., ForsbackG., SpeidelR., RippeB.In vitro biocompatibility of a heat-sterilized, low toxic, and less acidic fluid for peritoneal dialysis.Perit Dial Int1995; 15: 158–64.
27.
HendersonI.S., CouperI.A., LumsdenA.Potentially irritant glucose metabolites in unused CAPD fluid. In: MaherJ.F., WinchesterJ.F. eds. Frontiers in peritoneal dialysis.New York: Field Rich and Associates, 1986: 261–4.
28.
LoT.W.C., WestwoodM.E., McLellanA.C., SelwoodT., ThornalleyP.J.Binding and modification of proteins by methylglyoxal under physiological conditions.J Biol Chem1994; 269: 32299–305.
29.
KuykendallJ.R., BogdanffyM.S.Formation and stability of acetaldehyde-induced crosslinks between polylysine and poly -deoxyguanosine.Mutat Res1994; 311: 49–56.
30.
StenlakeJ.B.Pharmaceutical chemistry: utenda secunda artem.Pharmaceutic J1975; 215: 533–40.
31.
WolfromM.L., SchuetzR.D., CavalieriL.F.Chemical interactions of amino compounds and sugars. III The conversion of D-glucose to 5–(hydroxymethyl)-2furaldehyde.J Am Chem Soc1948; 70: 514–17.
32.
WolffS.P., JiangZ.Y., HuntJ.V.Protein glycation and oxidative stress in diabetes mellitus and ageing.Free Radic Biol Med1991; 10: 339–52.
33.
IgakiN., SakaiM., HataH., OimomiM., BabaS., KatoH.Effects of 3-deoxyglucosone on the Maillard reaction.Clin Chem1990; 36: 631–4.
34.
GokalR., KingJ., BogleS.Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicentre study.Lancet1987; ii: 1105–9.
35.
PollockC.A., IbelsL.S., CatersonR.J., MahonyJ.F., WaughD.A., CocksedgeB.Continuous ambulatory peritoneal dialysis: eight years of experience at a single centre.Medicine1989; 68: 293–308.
HeimburgerO., WaniewskiJ., WerynskiA., TranaeusA., LindholmB.Peritoneal fluid transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–506.
38.
HendersonI.S., CouperL.A., LumsdenA.The effect of shelf-life of peritoneal dialysis fluid on ultrafiltration in CAPD. In: La GrecaG., ChiaramonteS., FabrisA., FerianiM., RoncoC. eds. Peritoneal dialysis.Milano: Wichtig Editore, 1986: 85–6.
39.
StruijkD.G., KredietR.T., KoomenG.C.M.Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis.Nephron1991; 59: 213–20.
